Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bispecific antibody targeting sclerostin and DKK1
- Development stage
- Unknown
- Lead developer
- Angitia Biopharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
A bispecific antibody targeting both sclerostin (SOST) and Dickkopf-1 (DKK1), which are key negative regulators of the Wnt signaling pathway in bone metabolism. By simultaneously neutralizing both sclerostin and DKK1, the antibody promotes bone formation (osteoblastogenesis) and suppresses bone resorption (osteoclastogenesis), leading to rapid and robust gains in bone mineral density (BMD) and bone strength. This dual-targeting approach is designed to prevent the compensatory increases in DKK1 that typically limit the efficacy of sclerostin-only inhibitors. Clinical-stage candidates utilizing this mechanism, such as Angitia Biopharmaceuticals' AGA2118 and AGA2115, are being evaluated for the treatment of postmenopausal osteoporosis, osteogenesis imperfecta, and other bone-related disorders like renal osteodystrophy in chronic kidney disease (CKD).
- Other names
- anti-sclerostin/DKK1 bispecific antibodybispecific antibody against sclerostin and DKK1sclerostin x DKK1 bispecific antibodysclerostin/DKK1 bispecific antibody
02
Targets
DKK1 (Dickkopf-related protein 1)SOST (Sclerostin)
Beyond the preview
Go deeper on bispecific antibody targeting sclerostin and DKK1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bispecific antibody targeting sclerostin and DKK1.